It is anticipated that the FDA is about to approve a third new Alzheimer’s drug, Donanemab. The drug showed a 35% slowdown in cognitive decline in certain patients. To learn more about this drug and who can benefit, read the full article in SciTech Daily, click here.
Donanemab: The Breakthrough Drug Ushering a New Era in Alzheimer’s Treatment
Share This Story, Choose Your Platform!
About the Author: Gary Skole
Gary has a degree in business management from the University of Massachusetts. He has been the owner of a private duty home care agency since 1989 and continues as a partner in Home to Stay Healthcare Solutions in Cherry Hill NJ. He sits on a committee with the Home Care Association of America and speaks at national conferences on the subject of dementia.
Gary is also the founder and CEO of AlzBetter, a company which was created to address the needs of people living with dementia and offer support to those who care for them. He has authored several books and a video educational series on dementia care. Additionally, he has been recognized as a dementia leader and innovator winning the 2024 inaugural Home Health News Memory Care Innovation Award and CEO Monthly Magazine's Most Influential CEO Awards 2024
Leave A Comment